- Home
- CRIS vs ADIL Comparison
CRIS vs ADIL Comparison
Compare CRIS & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | ADIL |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 18.5M |
| IPO Year | 2000 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CRIS | ADIL |
|---|---|---|
| Price | $1.21 | $5.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $17.00 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 280.6K | 63.4K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,898,000.00 | N/A |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | $67.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.18 | $0.13 |
| 52 Week High | $6.74 | $7.20 |
Technical Indicators
Market Signals| Indicator | CRIS | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 22.67 | 58.97 |
| Support Level | $0.80 | $1.63 |
| Resistance Level | $1.21 | $6.41 |
| Average True Range (ATR) | 0.12 | 0.68 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 4.55 | 58.94 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.